KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples